FDA In Brief: Findings from Real-World Data Study Reveal Higher Risk of Hospitalization and Death Among Cancer Patients with COVID-19, Underscore Health Disparities

The following quote is attributed to Harpreet Singh, M.D., Associate Director, Cancer in Older Adults and Special Populations, FDA’s Oncology Center of Excellence; and Director, Division of Oncology 2, FDA’s Center for Drug Evaluation and Research

“The clinical experience of people with cancer who have contracted COVID-19 is an essential resource that can help the medical community better understand the impact of the disease in this population.

“The data we analyzed in collaboration with Syapse revealed a stark reality that people with cancer are at an increased risk of more serious outcomes from COVID-19 but also that there are inequities for Black Americans and those of lower socioeconomic means. It’s imperative that we continue to rapidly examine real-world data to address the urgent health care challenges brought on by this pandemic.

“In OCE, we will continue to work diligently to meet the needs of cancer patients, who constitute a vulnerable population at risk of contracting COVID-19.”

Additional Information:

  • The FDA’s Oncology Center of Excellence (OCE) and Syapse presented data at the American Association of Clinical Research (AACR) COVID-19 and Cancer meeting on an analysis of more than 212,000 health records of people living with cancer across two major health systems in the Midwestern United States.
  • The analysis found that cancer patients who also had COVID-19 are more likely (compared to those without COVID-19) to have: (1) other health conditions (e.g., kidney failure, obesity and heart disease), (2) increased rates of hospitalization and invasive mechanical ventilation, and (3) a 16-fold increased mortality risk. The researchers also underscored evidence for health care disparities among cancer patients with COVID-19.
  • This presentation is part of OCE’s partnerships with experts in healthcare data and analytics to investigate characteristics and clinical outcomes of patients with cancer who are infected with SARS-CoV-2, the virus that causes COVID-19. This work builds upon several initiatives under way across FDA that leverage real-world data to improve understanding of COVID-19. These efforts include FDA’s participation in the COVID-19 Evidence Accelerator, organized by the Reagan-Udall Foundation for the FDA in collaboration with Friends of Cancer Research.
  • The OCE continues to engage with stakeholders and collaborate with partners on opportunities to apply data from diverse sources to inform its understanding of COVID-19 in people with cancer.

Additional Resources:

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version